Peptide (small protein) medicines play an essential role in treating many serious diseases. Yet delivering them in a simple and effective way remains a scientific challenge. When taken orally, peptides are easily broken down by digestive enzymes, poorly absorbed through the gut, and largely removed by the liver before they can work.

One promising alternative is to deliver peptides through the lining of the mouth — particularly the inside of the cheek (buccal mucosa) or under the tongue (sublingual mucosa). These areas are rich in blood vessels and are generally well accepted by patients, making them a promising needle-free option.

However, the mouth is not an easy gateway. Saliva can quickly wash medicines away, natural enzymes may still break down peptides, and the mouth lining itself forms a tight protective barrier that limits how much drug can pass through. Achieving reliable and consistent absorption has therefore been a major hurdle.

To tackle this challenge, BUCCAL-PEP team member Sandeep Karki and colleagues at UCD explored the latest advances in the field in their new review paper published in Drug Delivery and Translational Research. The team examined the wide range of formulation strategies researchers have developed to improve peptide delivery through the mouth.

Permeation enhancers, mucoadhesive polymers and layered films

These approaches include substances that temporarily loosen the mouth lining to help drugs pass through (permeation enhancers), sticky materials that help dosage forms stay in place longer (mucoadhesive polymers), and layered thin films that carefully control how the drug is released. The review also highlights newer systems incorporating nanoparticles, which can protect delicate peptides from breakdown and help them cross the mouth lining more effectively.

Sandeep explains: “Our review systematically examines oromucosal films as a platform for delivering peptide medicines through the mouth, such as via the cheek (buccal) or under the tongue (sublingual). It focuses on how formulation design and key physicochemical properties of peptides can be used to overcome the biological barriers of the buccal and sublingual mucosa.”

Producing this review required carefully analysing and comparing a large body of scientific literature on buccal and sublingual peptide delivery. As Sandeep notes, “Results from multiple studies were brought together to identify common trends and challenges, and the findings were organised into a clear framework linking formulation design to potential clinical performance.”

Formulation strategies

A central theme quickly emerged: peptide delivery through the mouth lining is inherently difficult due to the strong biological barriers of the oral tissues and the relatively large molecular size of peptides. Yet there is reason for optimism. “However, these challenges can be addressed through rational formulation strategies and the appropriate use of permeation enhancers, making oromucosal delivery a promising non-injectable route,” Sandeep comments.

Importantly, the review emphasises that success does not come from a single ingredient or design tweak. “The key message is that successful peptide delivery through these routes requires an integrated formulation strategy rather than a single intervention. A clear understanding of oromucosal anatomy and physiology, together with the physicochemical properties of peptides, is essential to guide formulation choices, including film architecture, permeation enhancers, and nanocarrier systems.” Beyond the laboratory science, the team also stresses the importance of early consideration of safety, patient acceptability, and regulatory feasibility — all crucial factors in moving from promising research to real clinical applications.

One of the most compelling insights from the review relates to the power of structured film design. As Sandeep explains: “One of the most striking observations is the increasing evidence that rational film design, together with the appropriate use of permeation enhancers plays a critical role in improving peptide delivery. In particular, multilayer and nanoparticle-embedded mucoadhesion, and directional release, which helps overcome the anatomical and physiological barriers of the oral mucosa. When combined with a carefully selected polymer matrix, these structured film designs can work synergistically with permeation enhancers to improve peptide protection and mucosal transport, compared to conventional single-layer films, while ensuring patient comfort and safety.”

Building on this knowledge

Within BUCCAL-PEP, development of a multi-layer film is already underway. The insights from this review are helping to refine and optimise these systems, bringing the project another step closer to effective, patient-friendly peptide delivery through the mouth. More data — and exciting developments — are on the way.

Curious to read the full publication? Check it out here: 

Sandeep Karki

Sandeep is a PhD student at University College Dublin (UCD)

Graphical abstract of the review paper

Susie Birney

Patient Advocate

Susie lives in Dublin and volunteers her time to help advocate for others who live with obesity and Type 2 Diabetes. Most recently Susie was involved with Diabetes Ireland in the drafting of the “Talking about Diabetes : Language Matters” Guide. Addressing stigma for either Diabetes or Obesity which Susie has lived experience of,  is high on the list of her priorities and being involved in advisory boards is one example of how to do this by being involved throughout the research process from beginning to end.

Maura Murphy

Retired Civil Servant but currently Voluntary Secretary at ICPO the Irish Coalition for People Living with Obesity

Maura thinks it is important to treat the patient holistically. Over the years, she has been visiting several hospitals for different conditions, and these silos can be exhausting. She is passionate about learning about obesity since she discovered that it is a disease in 2019. Prior to that, her self-blame and stigma held her back. She has learned that obesity is a gateway to other diseases, and she knows this firsthand because she lives with Type 2 Diabetes, Hypertension, Gout, Fluid Retention, and Osteoarthritis. She attends a Chronic Disease Clinic in Ballina every six months, which has thankfully eliminated the silo appointments to three different hospitals and their various departments.

Mary Frances White

Social Care Worker within the community care system/ committee & patient representative for ICPO

Mary Frances is married with one adult child. She has worked for many years as a Social Care worker within Adult services for those with intellectual disabilities. She is SAM’s trained as she dispenses medication on a daily basis (SAM’s = Safe Administering of Medication).

She is also one of the first committee members and a patient representative for an ICPO. They give talks to medical students of many disciplines regarding respect and dignity for people living with obesity. They also hold weekly support meetings and face-to-face meetings when possible. The subject of medications that are becoming available for those who are living with obesity is very topical at present.

Ken Tait

Psychotherapist & International Diabetes Advocate

As a psychotherapist, Ken helps people navigate emotional problems. As a Diabetes Advocate, he supports individuals living with diabetes and advocates for the help and support they need. He serves on many local diabetes boards and gives talks both nationally and internationally to help people and healthcare professionals understand what living with type 2 diabetes is like.

The reason that he joined BUCCAL-PEP was that he likes to keep abreast of what is happening for people with diabetes and how they can manage their diabetes Additionally, he recognizes that some people dislike needles, and this BUCCAL-PEP approach could provide an alternative to help them.

Ken Tait

Psychotherapist & International Diabetes Advocate

As a psychotherapist, Ken helps people navigate emotional problems. As a Diabetes Advocate, he supports individuals living with diabetes and advocates for the help and support they need. He serves on many local diabetes boards and gives talks both nationally and internationally to help people and healthcare professionals understand what living with type 2 diabetes is like.

The reason that he joined BUCCAL-PEP was that he likes to keep abreast of what is happening for people with diabetes and how they can manage their diabetes Additionally, he recognizes that some people dislike needles, and this BUCCAL-PEP approach could provide an alternative to help them.

Javier O. Morales, Ph.D.

Biosketch

Dr. Javier O. Morales is an Associate Professor at the University of Chile, specializing in pharmaceutical science and technology. He heads the Center of New Drugs for Hypertension (CENDHY) and is an Associate Researcher in the Advanced Center for Chronic Diseases (ACCDiS). With a Ph.D. from The University of Texas at Austin, he focuses on innovative drug delivery systems, particularly for peptides, proteins, and poorly water-soluble drugs. His research explores nanoencapsulation and alternative routes of administration. Dr. Morales has a keen interest in buccal absorption and 2D/3D printing for drug delivery. He joined BUCCAL-PEP’s SAB to advance less invasive diabetes treatments and explore synergies with his own research.

Giovanni Traverso, MB, BChir, PhD

MIT and Harvard

Prof. Giovanni Traverso is the Director of the Laboratory for Translational Engineering at MIT and Harvard, an Associate Professor of Mechanical Engineering at MIT, an Associate Physician in Gastroenterology at Brigham and Women’s Hospital, Harvard Medical School, and an Associate Member of the Broad Institute. He received his undergraduate and medical degrees from Cambridge and a PhD from Johns Hopkins, where he pioneered non-invasive cancer detection. His postdoctoral research at MIT focused on advanced drug delivery and gastrointestinal sensing. His current work drives next-generation drug delivery systems and ingestible devices for physiological monitoring.

Prof. Ljiljana Fruk

University of Cambridge

Prof. Ljiljana Fruk is a Professor of Bionano Engineering at the Department of Chemical Engineering and Biotechnology at University of Cambridge.  Her research encompasses the design and development of nanoscale materials for biomedical applications, including design of drug nanocarriers for solid tumours and biosensors for early detection of cancer. She is particularly interested in development of nature-inspired structures, and has also made significant contributions to development of hybrid bio-nano materials and their application in photocatalysis and sustainable manufacturing. She is one of the co-founders of Senesys Bio, Cambridge spinout developing therapeutic formulations for senescent cell removal. Prof Fruk is an active science popularizer, art-science curator, and the co-author of the field-establishing Molecular Aesthetics book (MIT Press 2013), and the first textbook on Bionanotechnology (Cambridge University Press 2021).

Dr. Eva Roblegg

University of Graz

Dr. Eva Roblegg is a full professor at the University of Graz, specializing in pharmaceutical technology and biopharmacy. She leads the Drug Delivery and Advanced Manufacturing group and focuses on the development of nano drug delivery systems (nanoDDS) for the treatment of oral diseases, such as oral mucositis. To better understand the relationship between nanoDDS and buccal/sublingual tissues, her group has developed in vitro cell and tissue models that mimic healthy and inflamed human oral mucosa. Eva Roblegg works closely with the Research Center Pharmaceutical Engineering, a center of excellence in Graz, Austria, where she is involved in advanced technologies for the continuous manufacturing and conversion of (nano-)drug delivery systems into final dosage forms. Given her research interest in this area and the opportunity to create further synergies with her own research, she has joined BUCCAL-PEP’s SAB.

Dr. Andrew Muddle

MedPharm

Dr. Andrew Muddle, founder and former CEO of MedPharm, brings over 30 years of pharmaceutical industry experience in drug delivery. He played a pivotal role in PowderJect Pharmaceuticals plc’s early development and IPO, and his career includes positions at Elan Corporation, Ethical Pharmaceuticals Ltd (U.K.), Controlled Therapeutics (Scotland), and Ciba-Geigy (now Novartis). Dr. Muddle excels in managing projects to commercialization, specializing in transdermal and topical products. He joined BUCCAL-PEP due to the challenge of oral peptide delivery.